#1 Clinical Trials Search in Europe

TEV-53408

TEV-53408 is an investigational drug currently being studied in clinical trials for the treatment of autoimmune conditions including vitiligo and celiac disease. This medication is administered as a subcutaneous injection and aims to address the underlying immune responses in these conditions. Researchers are evaluating both the safety profile of TEV-53408 and its effectiveness in treating symptoms and improving quality of life for patients. The ongoing trials represent important steps toward potentially developing a new therapeutic option for patients with these challenging conditions.

Table of Contents

What is TEV-53408?

TEV-53408 is an investigational medication currently being studied for the treatment of autoimmune conditions, specifically vitiligo and celiac disease[1][2]. This medication is not yet approved for general use and is currently undergoing clinical trials to evaluate its safety and effectiveness.

Based on available clinical trial information, TEV-53408 appears to be designed to address the underlying immune system dysfunction in these conditions, though the exact mechanism of action is not fully described in the source materials[1][2].

How TEV-53408 Works

While the specific mechanism isn’t detailed in the clinical trial information, we can understand that TEV-53408 likely targets immune pathways involved in both vitiligo and celiac disease[1][2]. Both conditions have autoimmune components:

  • Vitiligo is a condition where the immune system attacks the body’s own pigment-producing cells (melanocytes), causing patches of skin to lose color[1].
  • Celiac disease is a condition where the immune system reacts to gluten (a protein found in wheat, barley, and rye), damaging the small intestine[2].

TEV-53408 is being investigated for its ability to modulate these immune responses, potentially reducing the autoimmune attack in both conditions[1][2].

TEV-53408 for Vitiligo Treatment

Vitiligo is a chronic condition that causes patches of skin to lose their color or pigment. It occurs when melanocytes (the cells that produce pigment) are destroyed by the body’s immune system[1].

A clinical trial (NCT06625177) is currently evaluating TEV-53408 for treating adults with vitiligo[1]. The trial aims to:

  • Assess the safety of TEV-53408 for vitiligo treatment
  • Explore how effective the medication might be for people with this condition

The study involves a 24-week treatment period, followed by a 16-week washout period (when no medication is given) and a 40-week follow-up period to monitor participants’ progress and any delayed effects[1].

TEV-53408 for Celiac Disease Treatment

Celiac disease is an autoimmune disorder where eating gluten leads to damage in the small intestine. When people with celiac disease eat gluten, their body mounts an immune response that attacks the small intestine, causing inflammation and damage to the villi (small, finger-like projections that line the small intestine and help absorb nutrients)[2].

A Phase 2a clinical trial (NCT06807463) is evaluating TEV-53408 for adults with celiac disease while they are exposed to gluten[2]. The main goals of this trial are to assess:

  • Whether TEV-53408 can reduce gluten-induced damage to the small intestine
  • The safety profile of TEV-53408 in people with celiac disease
  • Additional measures of how effective the treatment is

The trial is specifically measuring changes in villous atrophy (the flattening of the villi in the small intestine) using the villous height to crypt depth ratio (Vh:Cd). A lower ratio indicates more damage to the intestine. The study is also measuring changes in intraepithelial lymphocyte (IEL) density, which is an indicator of inflammation in the intestine[2].

How TEV-53408 is Administered

Based on the clinical trial information, TEV-53408 is administered as a subcutaneous injection[1][2]. Subcutaneous means the medication is injected just under the skin, similar to how insulin is often given to people with diabetes.

The exact dosing schedule and amount is not specified in the available information, as these details may vary depending on the specific trial and condition being treated[1][2].

Safety Information

As TEV-53408 is still in clinical trials, comprehensive safety information is not yet available. Both trials are carefully monitoring several safety outcomes[1][2], including:

  • Number of participants experiencing treatment-emergent adverse events (side effects that appear after treatment begins)
  • Number of participants with serious adverse events
  • Number of participants with protocol-defined adverse events of special interest (specific side effects that researchers are particularly watching for)
  • Number of participants who discontinue treatment due to adverse events

These safety measures are standard in clinical trials and help researchers determine if a medication is safe enough for wider use[1][2].

Current Clinical Trials

TEV-53408 is currently being evaluated in at least two clinical trials[1][2]:

  1. NCT06625177: A Phase 1b, open-label trial for vitiligo. This trial is primarily focused on safety assessment, with a total study period of 84 weeks per participant[1].
  2. NCT06807463: A Phase 2a, multicenter, randomized, double-blind, placebo-controlled trial for celiac disease. This trial is assessing both safety and efficacy, with a focus on whether TEV-53408 can protect the small intestine from damage when participants with celiac disease are exposed to gluten. The expected duration is approximately 86 weeks per participant[2].

These trials represent early to middle stages of clinical research. If these trials show promising results in terms of both safety and effectiveness, TEV-53408 may advance to larger Phase 3 trials before potentially seeking regulatory approval[1][2].

Feature Vitiligo Trial (NCT06625177) Celiac Disease Trial (NCT06807463)
Trial Phase Phase 1b Phase 2a
Trial Design Open-label Randomized, double-blind, placebo-controlled
Primary Objectives Evaluate safety of TEV-53408 Assess ability to attenuate gluten-induced enteropathy; Assess safety
Administration Subcutaneous injection Subcutaneous injection
Study Duration 84 weeks 86 weeks
Key Outcome Measures Adverse events, serious adverse events, treatment discontinuation Change in Vh:Cd ratio, adverse events, IEL density, VCIEL score
Treatment Period 24 weeks with 16-week washout and 40-week follow-up Not specifically stated in provided information

FAQ

  • What conditions is TEV-53408 being tested for? TEV-53408 is currently being tested in clinical trials for two autoimmune conditions: vitiligo (a condition causing loss of skin pigmentation) and celiac disease (an immune reaction to gluten that damages the small intestine). These trials aim to evaluate both the safety and effectiveness of the drug for these specific conditions.
  • How is TEV-53408 administered? TEV-53408 is administered as a subcutaneous injection. This means the medication is injected under the skin rather than into a muscle or vein. The clinical trials specify that the drug is provided as a solution for subcutaneous injection.
  • How long do the clinical trials for TEV-53408 last? The duration varies by condition. For the vitiligo trial, the planned study period per participant is 84 weeks, which includes a screening period (up to 4 weeks), a 24-week open-label treatment period, a 16-week washout period, and a 40-week follow-up period. For the celiac disease trial, the expected duration per participant is approximately 86 weeks.
  • What are the main goals of the TEV-53408 clinical trials? The main goals differ slightly between trials. For the vitiligo trial, the primary objective is to evaluate the safety of TEV-53408. For the celiac disease trial, there are dual primary objectives: to assess the ability of TEV-53408 to reduce gluten-induced damage to the intestines (enteropathy) and to evaluate the safety of the medication. Both trials include extensive monitoring of adverse events as key outcome measures.
  • Is there a placebo group in the TEV-53408 trials? The trial designs differ. The vitiligo trial (NCT06625177) is described as an open-label trial, which typically means all participants receive the active treatment. The celiac disease trial (NCT06807463) is explicitly described as a randomized, double-blind, placebo-controlled trial, meaning some participants will receive TEV-53408 while others will receive a placebo (an inactive substance that looks like the medication but contains no active ingredient).

Ongoing Clinical Trials on TEV-53408

  • Study of TEV-53408 Safety and Effectiveness in Adults with Celiac Disease During Gluten Exposure

    Not recruiting

    1
    Investigated drugs:
    Finland

Glossary

  • Vitiligo: A condition in which the skin loses its pigment cells (melanocytes), resulting in discolored patches of skin. It's considered an autoimmune disorder where the body's immune system attacks and destroys the melanocytes.
  • Celiac Disease: An autoimmune disorder where ingestion of gluten leads to damage in the small intestine. When people with celiac disease eat gluten, their immune system responds by damaging the small intestine's lining.
  • Subcutaneous: Referring to the tissue layer under the skin. A subcutaneous injection delivers medication into the fatty tissue between the skin and muscle.
  • Open-Label Trial: A type of clinical trial in which both the researchers and participants know which treatment is being administered. This differs from a blinded study, where this information is withheld.
  • Placebo-Controlled: A study design where some participants receive an inactive substance (placebo) that looks like the drug being tested to allow comparison of effects.
  • Double-Blind: A study design where neither the participants nor the researchers know who is receiving the active treatment versus placebo until after the trial is completed.
  • Randomized: A process where participants are assigned by chance to different treatment groups, helping to reduce bias in research results.
  • Adverse Event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure that may or may not be related to the treatment.
  • Serious Adverse Event: An adverse event that results in death, is life-threatening, requires hospitalization, causes a significant disability, or requires intervention to prevent permanent impairment.
  • Treatment-Emergent Adverse Event: An adverse event that appears or worsens during treatment in a clinical study.
  • Washout Period: A period during a clinical trial when participants receive no treatment so that the effects of a previous treatment can diminish or disappear before a new phase of the study begins.
  • Villous Atrophy: The erosion of the villi (tiny, finger-like projections) that line the small intestine, which reduces the surface area available for nutrient absorption. This is a characteristic finding in celiac disease.
  • Villous Height to Crypt Depth Ratio (Vh:Cd): A measurement used to assess the severity of celiac disease by comparing the height of intestinal villi to the depth of crypts (depressions between villi). A lower ratio indicates more damage to the intestinal lining.
  • Intraepithelial Lymphocyte (IEL): A type of white blood cell found in the epithelial layer of the intestines. An increased number of IELs is often seen in celiac disease and is used as a diagnostic marker.
  • Enteropathy: Any disease of the intestine, particularly the small intestine. In celiac disease, gluten-induced enteropathy refers to the damage to the small intestine caused by exposure to gluten.
  • VCIEL Score: A calculation used in celiac disease research that combines measurements of villous height to crypt depth ratio and intraepithelial lymphocyte density to assess intestinal damage.

References

  1. https://clinicaltrials.gov/study/NCT06625177
  2. https://clinicaltrials.gov/study/NCT06807463